Drug Trial Radar · NCT07834073
Immunogenicity and Safety of a Single Dose of mRNA SARS-CoV-2 Vaccine in Chinese Adults With Hybrid Immunity
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,052
Actual
Start
May 23, 2023
Primary completion
Feb 28, 2024
Study completion Feb 28, 2024
Sponsor
- Lead sponsor
- Jiangsu Province Centers for Disease Control and PreventionResearch network
- Sponsor type
- Research network
- First posted
- Sep 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a multicentre post-marketing cohort study to evaluate the immunogenicity and safety of a single dose of mRNA SARS-CoV-2 vaccine SYS6006 in Chinese adults predominantly with hybrid immunity. A total of 2,052 adults aged 18 years and older who received one dose of SYS6006 were monitored for serious adverse events (SAEs) for 6 months. The first 60 participants comprised an immunogenicity subgroup, with blood samples collected before vaccination and at day 14, month 3, and month 6 post-vaccination to assess humoral and cellular immune responses.
Conditions
- COVID-19
- SARS-CoV-2 Infection
Interventions
SYS6006Biological
Lipid nanoparticle (LNP)-encapsulated mRNA SARS-CoV-2 vaccine, 30 μg mRNA/0.3 mL, single intramuscular dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric mean titer (GMT) of neutralizing antibodies in the immunogenicity subgroupTime frame: 14 days after booster immunization
- Incidence of serious adverse events (SAEs)Time frame: Within 6 months after the booster administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jiangsu Provincial Center for Disease Control and Prevention
Nanjing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.